Cancer risk and low-penetrance susceptibility genes in gene-environment interactions

Journal of Clinical Oncology

Volumn 18, Issue 11, 2000, Pages 2309-2315

  Shields, Peter G ^a   Harris, Curtis C ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53;

CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SUSCEPTIBILITY; CIGARETTE SMOKING; DNA REPAIR; ENVIRONMENTAL EXPOSURE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TOBACCO; TUMOR SUPPRESSOR GENE;

EID: 0034089945     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.11.2309     Document Type: Review

References (65)

1. Ponder B: Genetic testing for cancer risk. Science 278:1050-1054, 1997
2. Doll R, Peto R: The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 66:1191-1308, 1981
3. Doll R: Nature and nurture: Possibilities for cancer control. Carcinogenesis 17:177-184, 1996
4. Garte S, Zocchetti C, Taioli E: Gene-environment interactions in the application of biomarkers of cancer susceptibility in epidemiology. IARC Sci Publ 251-264, 1997
5. Feigelson HS, Ross RK, Yu MC, et al: Sex steroid hormones and genetic susceptibility to breast and prostate cancer. Drug Metab Rev 30:421-434, 1998
6. Scottenfeld D, Fraumeni JF Jr: Cancer Epidemiology and Prevention. New York, NY, Oxford University Press, 1996
7. Perera FP: Molecular cancer epidemiology: a new tool in cancer prevention. J Natl Cancer Inst 78:887-898, 1987
8. Vineis P, Porta M: Causal thinking, biomarkers, and mechanisms of carcinogenesis. J Clin Epidemiol 49:951-956, 1996
9. Kato S, Bowman ED, Harrington AM, et al: Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. J Natl Cancer Inst 87:902-907, 1995
10. Ryberg D, Skaug V, Hewer A, et al: Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis 18:1285-1289, 1997
11. Vineis P: Molecular epidemiology: Low-dose carcinogens and genetic susceptibility. Int J Cancer 71:1-3, 1997
12. Nakachi K, Imai K, Hayashi S, et al: Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res 51:5177-5180, 1991
13. Okada T, Kawashima K, Fukushi S, et al: Association between a cytochrome P450 CYPIA1 genotype and incidence of lung cancer. Pharmacogen 4:333-340, 1995
14. Santella RM: DNA damage as an intermediate biomarker in intervention studies, Proc Soc Exp Biol Med 216:166-171, 1997
15. Hong WK, Sporn MB: Recent advances in chemoprevention of cancer. Science 278:1073-1077, 1997
16. Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318-1327, 1993
17. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88:323-331, 1997
18. Ko LJ, Prives C: p53: Puzzle and paradigm. Genes Dev 10:1054-1072, 1996
19. Harris CC: Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88:1442-1455, 1996
20. Greenblatt MS, Bennett WP, Hollstein M, et al: Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878, 1994
21. Brash DE, Rudolph JA, Simon JA, et al: A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 88:10124-10128, 1991
22. Ziegler A, Jonason AS, Leffell DJ, et al: Sunburn and p53 in the onset of skin cancer. Nature 372:773-776, 1994
23. Nakazawa H, English D, Randell PL, et al: UV and skin cancer: Specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. Proc Natl Acad Sci USA 91:360-364, 1994
24. Hsu IC, Metcalf RA, Sun T, et al: Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350:427-428, 1991
25. Bressac B, Kew M, Wands J, et al: Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350:429-431, 1991
26. Brennan JA, Boyle JO, Koch WM, et al: Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 332:712-717, 1995
27. Struewing JP, Hartge P, Wacholder S, et al: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408, 1997
28. Perera FP: Environment and cancer: Who are susceptible? Science 278:1068-1073, 1997
29. Warren AJ, Shields PG: Molecular epidemiology: Carcinogen DNA adducts and genetic susceptibility. Proc Soc Exp Biol Med 216:172-180, 1997
30. Fearon ER: Human cancer syndromes: Clues to the origin and nature of cancer. Science 278:1043-1050, 1997
31. Wei Q, Matanoski GM, Farmer ER, et al: DNA repair and aging in basal cell carcinoma: A molecular epidemiology study. Proc Natl Acad Sci USA 90:1614-1618, 1993
32. Liu Y, Hernandez AM, Shibata D, et al: BCL2 translocation frequency rises with age in humans. Proc Natl Acad Sci USA 91:8910-8914, 1994
33. Simpson AJ: The natural somatic mutation frequency and human carcinogenesis. Adv Cancer Res 71:209-240, 1997
34. Cloos J, Spitz MR, Schantz SP, et al: Genetic susceptibility to head and neck squamous cell carcinoma. J Natl Cancer Inst 88:530-535, 1996
35. Cloos J, Braakhuis BJ, Steen I, et al: Increased mutagen sensitivity in head-and-neck squamous-cell carcinoma patients, particularly those with multiple primary tumors. Int J Cancer 56:816-819, 1994
36. Spitz MR, Hsu TC, Wu X, et al: Mutagen sensitivity as a biological marker of lung cancer risk in African Americans. Cancer Epidemiol Biomarkers Prev 4:99-103, 1995
37. Shields PG: Genetic susceptibility to tobacco-related lung cancer, in Mendelsohn ML, Mohr LC, Peelers JP (eds): Medical and Workplace Applications of Biomarkers. Washington, DC, Joseph Henry Press, 1998, pp 241-252
38. Nakachi K, Imai K, Hayashi S, et al: Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with suscepability to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 53:2994-2999, 1993
39. Kihara M, Noda K: Risk of smoking for squamous and small cell carcinomas of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorphisms in a Japanese population. Carcinogenesis 16:2331-2336, 1995
40. Goto I, Yoneda S, Yamamoto M, Kawajiri K: Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res 56:3725-3730, 1996
41. Ishibe N, Wiencke JK, Zuo ZF, et al: Susceptibility to lung cancer in light smokers associated with CYP1A1 polymorphisms in Mexican- and African-Americans. Cancer Epidemiol Biomarkers Prev 6:1075-1080, 1997
42. Hamada GS, Sugimura H, Suzuki I, et al: The heme-binding region polymorphism of cytochrome P450IA1 (CypIA1). rather than the RsaI polymorphism of IIE1 (CypIIE1), is associated with lung cancer in Rio de Janeiro. Cancer Epidemiol Biomarkers Prev 4:63-67, 1995
43. Rebbeck TR: Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 6:733-743, 1997
44. McWilliams JE, Sanderson BJ, Harris EL, et al: Glutathione S-transferase M1 (GSTM1) deficiency and lung cancer risk. Cancer Epidemiol Biomarkers Prev 4:589-594, 1995
45. Bennett WP, Alavanja MC, Blomeke B, et al: Environmental tobacco smoke and genetic susceptibility as lung cancer risk factors in never-smoking women. J Natl Cancer Inst 91:2009-2014, 1999
46. Le Marchand L, Sivaraman L, Pierce L, et al: Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res 58:4858-4863, 1998
47. Ayesh R, Idle JR, Ritchie JC, et al: Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 312:169-170, 1984
48. Caporaso NE, Tucker MA, Hoover R, et al: Lung cancer and the debrisoquine metabolic phenotype. J Natl Cancer Inst 85:1264-1272, 1990
49. Uematsu F, Kikuchi H, Motomiya M, et al: Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn J Cancer Res 82:254-256, 1991
50. Uematsu F, Ikawa S, Kikuchi H, et al: Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: Possible relevance to low smoking exposure. Pharmacogenetics 4:58-63, 1994
51. Kawajiri K, Eguchi H, Nakachi K. et al: Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res 56:72-76, 1996
52. Ryberg D, Kure E, Lystad S, et al: p53-mutations in lung tumors. Relationship to putative susceptibility markers for cancer. Cancer Res 54:1551-1555, 1994
53. Lerman C, Caporaso NE, Main D, et al: Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 18:14-20, 1999
54. Hurt RD, Sachs DP, Glover ED, et al: A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337:1195-1202, 1997
55. Noble EP, St.Jeor ST, Ritchie T, et al: D2 dopamine receptor gene and cigarette smoking: A reward gene? Med Hypotheses 42:257-260, 1994
56. Comings DE, Ferry L, Bradshaw-Robinson S, et al: The dopamine D2 receptor (DRD2) gene: A genetic risk factor in smoking. Pharmacogen 6:73-79, 1996
57. Lerman C, Caporaso N, Main D, et al: Depression and self-medication with nicotine: The modifying influence of the dopamine D4 receptor gene. Health Psychol 17:56-62, 1998
58. Shields PG, Lerman C, Audrain J, et al: Dopamine D4 receptors and the risk of cigarette smoking in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 7:453-458, 1998
59. Kinzler KW, Vogelstein B: Gatekeepers and caretakers. Nature 386:761-763, 1997
60. Khoury MJ: Genetic epidemiology and the future of disease prevention and public health. Epidemiol Rev 19:175-180, 1997
61. McMichael AJ, Hall AJ: The use of biological markers as predictive early-outcome measures in epidemiological research. IARC Sci Publ 142:281-289, 1997
62. Burke W, Daly M, Garber J, et al: Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277:997-1003, 1997
63. Burke W, Petersen G, Lynch P, et al: Recommendations for follow-up care of individuals with an inherited predisposition to cancer: I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA 277:915-919, 1997
64. Giardiello FM, Brensinger JD, Petersen GM, et al: The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med 336:823-827, 1997
65. Holtzman NA, Murphy PD, Watson MS, et al: Predictive genetic testing: From basic research to clinical practice. Science 278:602-605, 1997